Fundraising FoxRed Tree Venture — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment.
BiotechDeep TechHealthtechMunich, DE
Jörg Wischhusen(Scientific Co-founder)Scott Clarke(Chief Executive Officer)inPeter Garcia(Chief Financial Officer)Sujata Rao(Chief Medical Officer)inStefan Ries(Chief Scientific Officer and Head of Munich Site)inAndrea Goddard(Chief Technical Officer)in
Co-investorsJeito CapitalBioqube VenturesForbionBayern KapitalBioGeneration VenturesCanaan Partners+2 more
SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases.
BiotechHealthtechMedical Devices
Ray Barlow(Chief Executive Officer)in
Co-investorsHealthCapBioqube VenturesForbionGimvMedicxi
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.